<DOC>
	<DOCNO>NCT00035932</DOCNO>
	<brief_summary>The purpose study learn well atazanavir ( ATV ) work combination ritonavir ( RTV ) saquinavir ( SQV ) tenofovir ( TDF ) nucleoside reduce viral load treatment experienced subject human immunodeficiency virus ( HIV ) . There comparison arm lopinavir ( LPV ) /RTV TDF nucleoside .</brief_summary>
	<brief_title>Atazanavir ( BMS-232632 ) Combination With Ritonavir Saquinavir , Lopinavir/Ritonavir , Each With Tenofovir Nucleoside Subjects With HIV</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Virologic failure 2 highly active antiretroviral therapy ( HAART ) regimens , total , include least one drug approve class protease inhibitor , nonnucleoside reverse transcriptase inhibitor , nucleoside reverse transcriptase inhibitor ( PI , NNRTI , NRTI ) : 1 . Currently fail HAART regimen 2 qualify plasma viral load measurement ( hospital/clinic value within 4 week screen viral load equivalent = &gt; 1,000 c/mL Roche Amplicor [ TM ] central lab measurement = &gt; 1,000 c/mL ( Roche Amplicor [ TM ] ) within 4 week randomization 2 . Cluster Differentiation 4 ( CD4 ) cell count = &gt; 50 cells/mm3 obtain within 4 week prior randomization = &gt; 16 year age ( minimum age determine local regulation legal requirement dictate ) ; History prior virologic response least one HAART regimen , define 1.0 log10 decline decline viral load &lt; 400 c/mL Roche Amplicor &lt; 500 c/mL Chiron Quantiplex branch DNA ( bDNA ) assay Both female child bear potential male must utilize effective barrier contraception reduce transmission sexually transmitted disease , include human immunodeficiency virus ( HIV ) . Other contraception addition barrier method permit ; interaction atazanavir oral contraceptive study . Subjects must able provide write informed consent ; Subjects available followup period least 48 week Baseline laboratory value measure within 2 week prior initiate study drug follow : 1. serum creatine &lt; 1.5 time upper limit normal ( ULN ) 2. total serum lipase &lt; 1.4 time ULN 3. liver enzyme alanine aminotransferase ( AST ) , aspartate aminotransferase ( ALT ) &lt; 3 time ULN 4. total serum bilirubin &lt; 1.5 time ULN Prior use ( = &gt; 3 day ) atazanavir , TVF LPV/RTV ; history SQV , must phenotypically sensitive current fail antiretroviral regimen must administer least eight week initiation screen must include PI NNRTI Presence newly diagnose HIVrelated opportunistic infection medical require acute therapy time enrollment Proven suspect acute hepatitis 30 day prior study entry . Subjects chronic hepatitis eligible provide liver function enzyme ( ALT/AST ) &lt; 3 x ULN Previous therapy agent significant systemic myelosuppressive , neurotoxic , pancreatoxic , hepatoxic cytotoxic potential within 3 month study start expect need therapy time enrollment therapy methadone ribavirin/interferons treatment neurotoxic drug drug affect Cytochrome P450 3A4 ( CYP3A4 ) . Active alcohol substance use sufficient , Investigator 's opinion , prevent adequate compliance study therapy increase risk develop pancreatitis chemical hepatitis Intractable diarrhea ( = &gt; 6 loose stools/day least 7 day consecutive day ) within 30 day prior study entry Pregnancy breastfeed History hemophilia Presence cardiomyopathy Any one following : 1 . Heart ratecorrected QT ( QTc ) interval &gt; 450 msec screen electrocardiogram ( EKG ) 2 . Heart rate &lt; 40 beat per minute ( bpm ) 3 . Pause length &gt; 3 second see EKG 4 . Clinical symptom potentially related heart block 5 . Third degree heart block History acute chronic pancreatitis If choose 2 ' 3 ' dideoxyinosine ( ddI ) 2',3'didehydro3'deoxythymidine ( d4T ) NRTI : History sign symptoms bilateral peripheral neuropathy = &gt; Grade 2 time screen Inability tolerate oral medication Any clinical condition prior therapy , opinion Investigator , would make subject unsuitable study unable comply dose requirement .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>